Journal of Clinical Pediatrics ›› 2024, Vol. 42 ›› Issue (10): 868-875.doi: 10.12372/jcp.2024.24e0778
• Original Article • Previous Articles Next Articles
LONG Xiaoru(
), YANG Ruling, ZHANG Zhenzhen, XU Hongmei, ZHAO Ruiqiu, ZHENG Gaihuan
Received:2024-07-31
Published:2024-10-15
Online:2024-10-08
LONG Xiaoru, YANG Ruling, ZHANG Zhenzhen, XU Hongmei, ZHAO Ruiqiu, ZHENG Gaihuan. Analysis of drug resistance and clinical characteristics of children with drug-resistant tuberculosis in Chongqing[J].Journal of Clinical Pediatrics, 2024, 42(10): 868-875.
"
| 药物 | 耐药菌 株数 | 耐药相关突变位点 | 突变率 [n(%)] |
|---|---|---|---|
| 异烟肼 | 37 | katG Ser315Thr | 28(75.7) |
| katG Ser140Asn | 0(0.0) | ||
| ahpC-54C>T | 0(0.0) | ||
| fabG1-15C>T和inhA Ile194Thr | 1(2.7) | ||
| fabG1-15C>T | 1(2.7) | ||
| 丙硫异 烟胺 | 5 | ethA Gln347* | 0(0.0) |
| ethA 140_140del | 1(20.0) | ||
| ethA 938_939insT | 1(20.0) | ||
| fabG1-15C>T | 1(20.0) | ||
| fabG1-15C>T和inhA Ile194Thr | 1(20.0) | ||
| 利福平 | 19 | rpoB Leu430Pro | 1(5.3) |
| rpoB Asp435Ala和Leu452Pro | 1(5.3) | ||
| rpoB Asp435Tyr和Asn437Asp | 2(10.5) | ||
| rpoB His445Asn | 1(5.3) | ||
| rpoB His445Asp | 1(5.3) | ||
| rpoB His445Leu | 0(0.0) | ||
| rpoB His445Tyr | 1(5.3) | ||
| rpoB Ser450Leu | 10(52.6) | ||
| rpoB Ser450Leu和rpoC Leu527Val | 1(5.3) | ||
| 利福喷丁 | 23 | rpoB Leu430Pro | 0(0.0) |
| rpoB Asp435Ala和Leu452Pro | 1(4.3) | ||
| rpoB Asp435Tyr和Asn437Asp | 2(8.7) | ||
| rpoB His445Asn | 1(4.3) | ||
| rpoB His445Asp | 1(4.3) | ||
| rpoB His445Leu | 1(4.3) | ||
| rpoB His445Tyr | 1(4.3) | ||
| rpoB Ser450Leu | 12(52.2) | ||
| rpoB Ser450Leu和rpoC Leu527Val | 1(4.3) | ||
| 乙胺丁醇 | 21 | embB Met306Val | 5(23.8) |
| embB Met306Ile | 1(4.8) | ||
| embB Met306Leu和embA -12C>T | 1(4.8) | ||
| embB Ala356Val | 0(0.0) | ||
| embB Ser380Asn | 0(0.0) | ||
| embB Gly406Ala | 1(4.8) | ||
| embB Gly406Asp | 1(4.8) | ||
| embB Gly406Ser | 0(0.0) | ||
| embB Gln497Arg | 1(4.8) | ||
| 左氧氟 沙星 | 9 | gyrA Ala90Val | 2(22.2) |
| gyrA Ala90Val和Ser91Pro | 1(11.1) | ||
| gyrA Asp94Gly | 5(55.6) | ||
| gyrB Asn499Asp | 0(0.0) | ||
| gyrB Thr500Asn | 0(0.0) | ||
| gyrB Glu501Asp | 0(0.0) | ||
| 莫西沙星 | 12 | gyrA Ala90Val | 3(25.0) |
| gyrA Ala90Val和Ser91Pro | 1(8.3) | ||
| gyrA Asp94Gly | 6(50.0) | ||
| gyrB Asn499Asp | 0(0.0) | ||
| gyrB Thr500Asn | 0(0.0) | ||
| gyrB Glu501Asp | 1(8.3) | ||
| 阿米卡星 | 3 | rrs 1401a>g | 3(100) |
"
| 项 目 | 敏感组(n=240) | 耐药组(n=51) | 统计量 | P |
|---|---|---|---|---|
| 男性[n(%)] | 126(52.5) | 14(27.5) | χ2=10.57 | 0.001 |
| 年龄[n(%)] | χ2=0.37 | 0.947 | ||
| 0~4岁 | 75(31.2) | 18(35.3) | ||
| 5~9岁 | 42(17.5) | 8(15.7) | ||
| 10~14岁 | 105(43.8) | 21(41.2) | ||
| 15~18岁 | 18(7.5) | 4(7.8) | ||
| 民族[n(%)] | χ2=0.75 | 0.386 | ||
| 汉族 | 211(87.9) | 47(92.2) | ||
| 少数民族 | 29(12.1) | 4(7.8) | ||
| 居住地[n(%)] | χ2=0.07 | 0.788 | ||
| 城市 | 80(33.3) | 18(35.3) | ||
| 农村 | 160(66.7) | 33(64.7) | ||
| 治疗状态[n(%)] | χ2=10.85 | 0.001 | ||
| 初治 | 238(99.2) | 46(90.2) | ||
| 复治 | 2(0.8) | 5(9.8) | ||
| 有结核病接触史[n(%)] | 89(37.1) | 25(49.0) | χ2=2.52 | 0.113 |
| 有卡介苗接种史[n(%)] | 191(79.6) | 30(58.8) | χ2=9.92 | 0.002 |
| 有效治疗前症状持续时长[M(P25~P75)]/d | 29.1(15.9~60.0) | 18.9(10.8~46.8) | Z=0.10 | 0.923 |
| 住院次数[M(P25~P75)]/次 | 1.0(1.0~4.0) | 2.0(1.0~5.3) | Z=0.24 | 0.817 |
| 重症结核病[n(%)] | 150(62.5) | 44(86.3) | χ2=10.70 | 0.001 |
| 诊断[n(%)] | χ2=7.29 | 0.026 | ||
| 肺结核 | 119(49.5) | 16(31.4) | ||
| 肺外结核 | 3(1.3) | 0(0.0) | ||
| 肺结核合并肺外结核 | 118(49.2) | 35(68.6) | ||
| 治疗用药[n(%)] | χ2=48.25 | <0.001 | ||
| 一线药物 | 177(73.8) | 27(52.9) | ||
| 一线加二线药物 | 59(24.5) | 10(19.6) | ||
| 二线药物 | 4(1.7) | 14(27.5) | ||
| 治疗结局[n(%)] | χ2=6.77 | 0.009 | ||
| 治愈或治疗完成 | 229(95.4) | 43(84.3) | ||
| 治疗失败或死亡 | 11(4.6) | 8(15.7) |
"
| 项 目 | 敏感组(n=237) | 耐药组(n=51) | χ2值 | P |
|---|---|---|---|---|
| 病变位置 | 7.96 | 0.019 | ||
| 左侧 | 37(15.6) | 2(3.9) | ||
| 右侧 | 70(29.5) | 11(21.6) | ||
| 双侧 | 130(54.9) | 38(74.5) | ||
| 累及肺叶数量 | 11.54 | 0.021 | ||
| 1叶 | 40(16.9) | 3(5.9) | ||
| 2叶 | 54(22.8) | 6(11.8) | ||
| 3叶 | 38(16.0) | 7(13.7) | ||
| 4叶 | 22(9.3) | 9(17.6) | ||
| 5叶 | 83(35.0) | 26(51.0) | ||
| 累及肺叶部位 | ||||
| 左上叶 | 151(63.7) | 36(70.6) | 0.87 | 0.351 |
| 左下叶 | 163(68.8) | 32(62.7) | 0.70 | 0.403 |
| 右上叶 | 175(73.8) | 39(76.5) | 0.15 | 0.696 |
| 右中叶 | 154(65.0) | 40(78.4) | 3.46 | 0.063 |
| 右下叶 | 157(66.2) | 42(82.4) | 5.10 | 0.024 |
| 病变类型 | ||||
| 树芽征 | 7(3.0) | 2(3.9) | 0.12 | 0.726 |
| 实变 | 52(21.9) | 10(19.6) | 0.14 | 0.713 |
| 钙化 | 56(23.6) | 10(19.6) | 0.38 | 0.535 |
| 坏死 | 6(2.5) | 7(13.7) | 9.20 | 0.002 |
| 空洞 | 45(19.0) | 7(13.7) | 0.79 | 0.376 |
| 肺不张 | 40(16.9) | 11(21.6) | 0.63 | 0.426 |
| 粟粒性病变 | 31(13.1) | 7(13.7) | 0.02 | 0.902 |
| 结节影 | 55(23.2) | 8(15.7) | 1.39 | 0.239 |
| 支气管充气征 | 22(9.3) | 9(17.6) | 3.06 | 0.080 |
| 支气管扩张 | 31(13.1) | 12(23.5) | 3.61 | 0.058 |
| 支气管狭窄 | 37(15.6) | 13(25.5) | 2.86 | 0.091 |
| 淋巴结病变 | 181(76.4) | 41(80.4) | 0.38 | 0.535 |
| 胸膜病变 | 74(21.2) | 15(29.4) | 0.07 | 0.799 |
| 胸腔积液 | 63(26.6) | 13(25.5) | 0.03 | 0.872 |
"
| 项 目 | 敏感组(n=240) | 耐药组(n=51) | χ2值 | P |
|---|---|---|---|---|
| 抗酸染色涂片 | 5.50 | 0.019 | ||
| ≥1次阳性 | 68(28.3) | 23(45.1) | ||
| 全部阴性 | 172(71.7) | 28(54.9) | ||
| TST | 7.55 | 0.056 | ||
| 阴性 | 87(36.2) | 27(52.9) | ||
| 一般阳性 | 25(10.4) | 1(2.0) | ||
| 中度阳性 | 39(16.3) | 5(9.8) | ||
| 强阳性 | 89(37.1) | 18(35.3) | ||
| T-SPOT.TB阳性 | 222(92.5) | 42(82.4) | 4.40 | 0.036 |
| Xpert MTB/RIF | 3.61 | 0.058 | ||
| ≥1次阳性 | 150(62.5) | 39(76.5) | ||
| 全部阴性 | 90(37.5) | 12(23.5) | ||
| TB-DNA | 0.76 | 0.384 | ||
| ≥1次阳性 | 81(33.8) | 14(27.5) | ||
| 全部阴性 | 159(66.2) | 37(72.5) |
| [1] | World Health Organization. Global tuberculosis report 2022 [EB/OL]. Geneva: World Health Organization, 2022 [2024-8-22]. http://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022. |
| [2] | Schaaf HS, Hughes J. Current treatment of drug-resistant tuberculosis in children[J]. Indian J Pediatr, 2024, 91(8): 806-816. |
| [3] | Guo Q, Pan Y, Yang Z, et al. Epidemiology and clinical characteristics of pediatric drug-resistant tuberculosis in Chongqing, China[J]. PLoS One, 2016, 11(3): e0151303. |
| [4] |
Zhang Y, Zhao R, Zhang Z, et al. Analysis of factors influencing multidrug-resistant tuberculosis and validation of whole-genome sequencing in children with drug-resistant tuberculosis[J]. Infect Drug Resist, 2021, 14: 4375-4393.
doi: 10.2147/IDR.S331890 pmid: 34729015 |
| [5] | World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis. Tests for tuberculosis infection[M/OL]. Geneva: World Health Organization, 2022. |
| [6] | 赵雁林, 逄宇. 结核病实验室检验规程[M]. 北京: 人民卫生出版社, 2015. |
| [7] | 张颖, 任巧丽, 赵瑞秋, 等. 儿童抗结核药物耐药比例法、微孔板法、全基因组测序检测对比研究[J]. 临床儿科杂志, 2023, 41(2): 117-124. |
| [8] |
Wiseman CA, Gie RP, Starke JR, et al. A proposed comprehensive classification of tuberculosis disease severity in children[J]. Pediatr Infect Dis J, 2012, 31(4): 347-352.
doi: 10.1097/INF.0b013e318243e27b pmid: 22315002 |
| [9] | Linh NN, Viney K, Gegia M, et al. World Health Organization treatment outcome definitions for tuberculosis: 2021 update[J]. Eur Respir J, 2021, 58(2):2100804. |
| [10] | 中华人民共和国国家卫生和计划生育委员会. 肺结核诊断标准(WS 288-2017)[J]. 新发传染病电子杂志, 2018, 3(1): 59-61. |
| [11] | Lam C, Martinez E, Crighton T, et al. Value of routine whole genome sequencing for Mycobacterium tuberculosis drug resistance detection[J]. Int J Infect Dis, 2021, 113 Suppl 1: S48-S54. |
| [12] | Zhao J, Qian C, Jiang Y, et al. Drug-resistant characteristics, genetic diversity, and transmission dynamics of multidrug-resistant Mycobacterium tuberculosis in Jiangxi, China[J]. Infect Drug Resist, 2024, 17: 2213-2223. |
| [13] | Imran M. Ethionamide and prothionamide based coumarinyl-thiazole derivatives: synthesis, antitubercular activity, toxicity investigations and molecular docking studies[J]. Pharm Chem J, 2022, 56(9): 1215-1225. |
| [14] | Ma P, Luo T, Ge L, et al. Compensatory effects of M. tuberculosis rpoB mutations outside the rifampicin resistance-determining region[J]. Emerg Microbes Infect, 2021, 10(1): 743-752. |
| [15] | Fisher C, Patel R. Rifampin, rifapentine, and rifabutin are active against intracellular periprosthetic joint infection-associated Staphylococcus epidermidis[J]. Antimicrob Agents Chemother, 2021, 65(2):e01275-20. |
| [16] |
Naz F, Ahmad N, Wahid A, et al. High rate of successful treatment outcomes among childhood rifampicin/multidrug-resistant tuberculosis in Pakistan: a multicentre retrospective observational analysis[J]. BMC Infect Dis, 2021, 21(1): 1209.
doi: 10.1186/s12879-021-06935-6 pmid: 34863099 |
| [17] | Jia H, Xu Y, Sun Z. Analysis on drug-resistance-associated mutations among multidrug-resistant Mycobacterium tuberculosis isolates in China[J]. Antibiotics (Basel), 2021, 10(11): 1367. |
| [18] | Chauffour A, Morel F, Reibel F, et al. A systematic review of Mycobacterium leprae DNA gyrase mutations and their impact on fluoroquinolone resistance[J]. Clin Microbiol Infect, 2021, 27(11): 1601-1612. |
| [19] | Singh PK, Singh U, Jain A. Emergence of specific gyrA mutations associated high-level fluoroquinolone-resistant Mycobacterium tuberculosis among multidrug-resistant tuberculosis cases in North India[J]. Microb Drug Resist, 2021, 27(5): 647-651. |
| [20] |
Kabir S, Tahir Z, Mukhtar N, et al. Fluoroquinolone resistance and mutational profile of gyrA in pulmonary MDR tuberculosis patients[J]. BMC Pulm Med, 2020, 20(1): 138.
doi: 10.1186/s12890-020-1172-4 pmid: 32393213 |
| [21] | Lu Z, Jiang W, Zhang J, et al. Drug resistance and epidemiology characteristics of multidrug-resistant tuberculosis patients in 17 provinces of China[J]. PLoS One, 2019, 14(11): e0225361. |
| [22] | Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment-2017; Ahmad N, Ahuja SD, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis[J]. Lancet, 2018, 392(10150): 821-834. |
| [23] | Islam MM, Tan Y, Hameed HMA, et al. Prevalence and molecular characterization of amikacin resistance among Mycobacterium tuberculosis clinical isolates from southern China[J]. J Glob Antimicrob Resist, 2020, 22: 290-295. |
| [24] | 张春华, 李涛, 杜昕, 等. 2019-2021年我国4省份报告儿童肺结核病例特征分析[J]. 中华流行病学杂志, 2022, 43(11): 1739-1745. |
| [25] | Li CH, Fan X, Lv SX, et al. Clinical and computed tomography features associated with multidrug-resistant pulmonary tuberculosis: a retrospective study in China[J]. Infect Drug Resist, 2023, 16: 651-659. |
| [26] | Negi K, Bhaskar A, Dwivedi VP. Progressive host-directed strategies to potentiate BCG vaccination against tuberculosis[J]. Front Immunol, 2022, 13: 944183. |
| [27] | Xu Y, Li Q, Zhu M, et al. The epidemiological characteristics and profile of drug-resistant tuberculosis among children with tuberculosis in Sichuan, China, 2015-2018: A retrospective study[J]. Medicine (Baltimore), 2020, 99(43): e22608. |
| [28] | Song QS, Zheng CJ, Wang KP, et al. Differences in pulmonary nodular consolidation and pulmonary cavity among drug-sensitive, rifampicin-resistant and multi-drug resistant tuberculosis patients: a computerized tomography study with history length matched cases[J]. J Thorac Dis, 2022, 14(7): 2522-2531. |
| [29] | 廖琼, 谭珊, 朱渝, 等. 儿童耐药结核病的临床特点及二线抗结核治疗效果分析[J]. 中华儿科杂志, 2017, 55(2): 100-103. |
| [30] |
Wang Y, Sun Q, Zhang Y. Systemic immune dysregulation in severe tuberculosis patients revealed by a single-cell transcriptome atlas[J]. J Infect, 2023, 86(5): 421-438.
doi: 10.1016/j.jinf.2023.03.020 pmid: 37003521 |
| [1] | LIN Jinfeng, CHEN Yi, DENG Yan, FENG Ai, HUANG Juan, CHEN Lizhu, XIE Jingqi, NIE Xiaojing. A comparative study on the detection of anti-Nephrin antibodies in children's nephrotic syndrome by chemiluminescence method and cell-based assay [J]. Journal of Clinical Pediatrics, 2026, 44(8): 682-689. |
| [2] | ZHENG Fangyuan, WANG Miao, DING Mingming, LU Aidong, JIA Yueping, ZENG Huimin, ZHANG Leping. Next-generation sequencing identified gene variants and their prognostic impact in pediatric Philadelphia chromosome positive acute lymphoblastic leukemia [J]. Journal of Clinical Pediatrics, 2026, 44(8): 690-697. |
| [3] | ZHANG Xiao, FANG Hongjun, KUANG Xiaojun, WANG Lijuan, WU Zhao, JIANG Sha, LI Pei, WU Liwen. Analysis of the clinical and electrophysiological characteristics of atonic seizures in children [J]. Journal of Clinical Pediatrics, 2026, 44(8): 698-704. |
| [4] | WANG Mengqian, YANG Hui. Case series analysis of 13 intestinal Behcet’s syndrome in children [J]. Journal of Clinical Pediatrics, 2026, 44(8): 705-711. |
| [5] | WU Xirong, GAO Qi, GUO Siyuan, YIN Qingqin, QIN Qiang, YIN Ju, JIAO Anxia, CHEN Chenghao, WU Di, WANG Bei, DUAN Xiaomin, PENG Yun, XU Baoping, GAO Liwei. Clinical characteristics and prognosis of pulmonary mucormycosis in children with diabetes mellitus [J]. Journal of Clinical Pediatrics, 2026, 44(8): 712-720. |
| [6] | HAN Yanan, GE Lanlan, CUI Jieyuan. A case report of branchio-oto-renal syndrome caused by EYA1 gene variant with a 6-year follow-up [J]. Journal of Clinical Pediatrics, 2026, 44(8): 721-726. |
| [7] | SHI Jiayi, GAO Chunlin, JIA Lili, LU Yunyun, SUN Tao, ZHU Xiaodong, XIA Zhengkun, ZHANG Pei. Phenotypic characteristics and prognostic analysis of a pedigree with childhood isolated nephrotic syndrome caused by compound heterozygous mutations in the COQ2 gene [J]. Journal of Clinical Pediatrics, 2026, 44(8): 727-732. |
| [8] | DING Qiuyuan, ZHOU Liang. Research progress of pediatric intensive care unit-acquired weakness [J]. Journal of Clinical Pediatrics, 2026, 44(8): 755-762. |
| [9] | Rachel Rosen, Osvaldo Borrelli, Christophe Faure, Katja Karrento, Usha Krishnan, Samuel Nurko, Nathalie Rommel, Alan Silverman, Michiel van Wijk, Marc Benninga (Author), Chinese Medical Association Parenteral and Enteral Nutrition Branch Pediatrics Group, The Subspecialty Group of Gastroenterology, The Society of Pediatric, Chinese Medical Association, Gastroenterology Group, Pediatrician Branch, Chinese Medical Doctor Association (Translator). Core interpretation and explanation of Rome Ⅴ diagnostic criteria: upper gastrointestinal disorders of gut-brain interaction in children and adolescents [J]. Journal of Clinical Pediatrics, 2026, 44(7): 595-608. |
| [10] | Carlo Di Lorenzo, Miguel Saps, Bruno P. Chumpitazi, Shaman Rajindrajith, Annamaria Staiano, Nikhil Thapar, Miranda van Tilburg, Carlos Velasco-Benítez, Arine Vlieger (Author), Chinese Medical Association Parenteral and Enteral Nutrition Branch Pediatrics Group, The Subspecialty Group of Gastroenterology, The Society of Pediatric, Chinese Medical Association, Gastroenterology Group, Pediatrician Branch, Chinese Medical Doctor Association (Translator). Core interpretation and explanation of Rome Ⅴ diagnostic criteria: lower and biliary disorders of gut-brain interaction in children and adolescents [J]. Journal of Clinical Pediatrics, 2026, 44(7): 609-621. |
| [11] | LI Xufeng, TANG Haoxun, LI Xingjun, ZHANG Lize, GAO Chenqing, ZHAO Shunying, LIU Jianhua. Clinical characteristics, chest CT imaging phenotypes, and their correlation with prognosis in 76 children with Chlamydia pneumoniae pneumonia [J]. Journal of Clinical Pediatrics, 2026, 44(7): 622-627. |
| [12] | WANG Zhen, SHAO Jingbo, ZHANG Na, XIA Min, ZHU Jiashi, DU Chengkan, LI Hong. Factors influencing long-term recurrence in pediatric acute lymphoblastic leukemia patients with low-risk disease at initial diagnosis: a five-year follow-up analysis of 254 cases from a single center [J]. Journal of Clinical Pediatrics, 2026, 44(7): 628-635. |
| [13] | GUO Xuemei, XUE Yao, WANG Yongren, RONG Liucheng, FANG Yongjun, LIN Rufeng. Clinical features and prognosis of childhood acute myeloid leukemia with CBFA2T3::GLIS2 fusion [J]. Journal of Clinical Pediatrics, 2026, 44(7): 636-643. |
| [14] | YANG Lijun, FU Dongxia, CUI Yan, YANG Junmei, ZHANG Liming. Clinical manifestation and genetic analysis of CHARGE syndrome caused by CHD7 gene variation [J]. Journal of Clinical Pediatrics, 2026, 44(7): 644-650. |
| [15] | HU Yan, YANG Fan, LIANG Aimin, MAO Meng. Identification and management of faltering growth in children: insights from the 13th International Conference on Nutrition and Growth [J]. Journal of Clinical Pediatrics, 2026, 44(6): 485-488. |
|
||